Company profile
Instadose Pharma Corp.
OTC: INSD · Healthcare · Drug Manufacturers - Specialty & Generic
#1149 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 12GM —SS 17
v0.1 · 25/100 weight · pillars only
↑ Altman-Z, Piotroski F · ↓ disclosure history, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$462.0k
Employees
2
as of 2026-08-28
Market cap
$53.2k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.7k$2.7k2018
Net income-$462.0k-$462.0k2021
Operating income-$106.4k-$106.4k2020
Total assets$0$02021
Equity-$162.3k-$162.3k2021
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Instadose Pharma Corp.’s revenue?
Instadose Pharma Corp. booked $2.7k in FY2018 revenue — among the slowest-growing Healthcare companies we track, at a -17017.4% net margin.
Peers · Healthcare
Biora Therapeutics, Inc.——Aditxt, Inc.18DAccelera Innovations, Inc——Aibotics Inc.14DAtossa Therapeutics, Inc.30DQuantum Medical Transport, Inc.——Neighbors
Chesapeake (Independent City) →Key facts
CEOAntonio Rocco Franchino
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersChesapeake, VA
ExchangeOTC: INSD
Employees2
IPO date2020-10-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.